The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy.

The genetic evaluation of dilated cardiomyopathy (DCM) has been challenging, owing in large part to marked genetic heterogeneity. However, lower costs from next-generation sequencing have enabled gene discovery and the expansion of genetic testing panels. These advances have improved molecular diagnostics and predictive testing in DCM. We provide a rationale and recommendation for clinical genetic testing in all DCM cases.

Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Be the first to comment

Leave a Reply

Your email address will not be published.


*